Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of UBT251 injection in type 2 diabetes mellitus
ChiCTR2500109201Phase 2Completed
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UBT251 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by The Second Xiangya Hospital. Primary endpoint: Change From Baseline in HbA1c at Week 24. Started Sep 2025; status: completed.
02
Drugs
UBT251
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500109201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109201.